Up at 5AM: The 5AM Solutions Blog

Getting Drugs to (More) Patients - Global Edition

Posted on Tue, May 12, 2015 @ 04:30 PM

The newest installments in the Map of Biomedicine blog posts take us down the routes that get drugs to patients, primarily in the United States. Of course, we are all patients at one time or other regardless of where we live. Without a doubt, the route to getting effective therapies from the lab to your local pharmacist is convoluted and expensive even if you live in a wealthy nation. If you don't, making the most effective treatments available to the people who need them most in middle- and low-income nations is more difficult.   

Read More

Tags: map of biomedicine, drug development, drugs, World Health Oranization

Clinical Trial Basics on the Map of Biomedicine

Posted on Thu, May 07, 2015 @ 02:00 PM

As I said in my last post, one of the key components of the Map of Biomedicine is how new treatments get developed. That’s one of the parts of the map that is highlighted, as shown below.

Read More

Tags: clinical trials, biomedicine, map of biomedicine, drug development, Vignette 2

Drug Development and Discovery Going Viral

Posted on Thu, Mar 19, 2015 @ 03:00 PM

Last week, a Reddit user posted a link to an interesting project via the social media site’s You Should Know sidebar. It began, “YSK you can send a scoop of dirt from your backyard to a research group that will analyze it for new antibiotic elements and other medicines.

Read More

Tags: cancer, drug development

The Comeback Kids: Old Drugs, New Uses

Posted on Tue, Mar 03, 2015 @ 03:00 PM

Drug development is a long, expensive process with a very high failure rate. In a 2011 commentary in the journal Science Translational Medicine, NIH director Francis Collins described it like this:

Read More

Tags: clinical trials, drug development, drugs

Banking on a Cancer "Off Switch"

Posted on Tue, Feb 24, 2015 @ 03:30 PM

On Sunday, the Wall Street Journal published a business story (login required for the full story) about a new approach to treating cancer, and particularly a few late stage cancers. According to the story, investors like Michael Milken, George Soros, Jeff Bezos and Paul Allen are among best-known names betting on an emerging sector of cancer drug development called immunotherapy

Read More

Tags: cancer, Innovations, drug development, immunotherapy

Potentially, A Key to HIV

Posted on Thu, Feb 19, 2015 @ 03:00 PM

A team of researchers led by Michael Farzan from The Scripps Research Institute in Jupiter, FL may be on the cusp of identifying the biggest drug threat to HIV in the 30-year struggle against AIDS. Farzan and his team exploited the AIDS virus' own biomechanics to prevent it from invading healthy white blood cells. 

Read More

Tags: HIV, AIDS, drug development

Alzheimer's Disease in 3D

Posted on Tue, Jan 13, 2015 @ 03:00 PM

The National Institute on Aging estimates that about 5 million Americans over the age of 65 have Alzheimer's Disease (AD). In general, as people get older, they become more susceptible to this irreversible, degenerative brain disease. In fact, the prevalence of AD doubles every five years after age 65, and while AD is not "normal" aging, as the population ages the numbers of cases of AD will increase commensurately. To put that into perspective, by 2050, 20% of the population will be 65 years old and older.

Read More

Tags: research, drug development, Alzheimer's Disease

Today in Drug Development: New Antibiotics on the Horizon?

Posted on Thu, Jan 08, 2015 @ 04:30 PM

Although any clinical applications are many years away, there is hopeful news in the world of antibiotics. Researchers from Northeastern University in Boston published a paper in Nature yesterday reporting that they had found a method of extracting antibiotics from dirt-dwelling bacteria. 

Read More

Tags: drug development, antibiotics

Clinical Trials: Finding Goldilocks to Cure Rare Diseases

Posted on Tue, Dec 09, 2014 @ 03:00 PM

One of the challenges in drug development is enrolling participants in clinical trials that meet very specific criteria. The reason for this is sound: make the trial too broad and researchers risk missing meaningful data about a potential therapy's efficacy.

However, there is a tension between mitigating that risk and the need to reach as many people with horribly debilitating -- and often life-threatening -- illnesses as possible with a life-altering miracle.  Often multiple trials have to be conducted that test lots of different scenarios, and each one needs participants whose conditions, like the porridge and the bed in the fairy tale, are "just right."

Read More

Tags: clinical trials, rare diseases, drug development


Diagnostic Tests on the Map of Biomedicine


Download the ebook based on our popular blog series. This free, 50+ page edition features updated, expanded posts and redesigned, easier-to-read maps. 

FREE Biobanking Ebook

Biobanking Free Ebook
Get this 29 page PDF document on how data science can be used to advance biorepositories.

 Free NGS Whitepaper

NGS White Paper for Molecular Diagnostics

Learn about the applications, opportunities and challenges in this updated free white paper. 

Recent Posts